“We know that women with inflammatory bowel disease when they are pregnant are at increased risk for adverse pregnancy outcomes,” Sunanda V. Kane, MD, a gastroenterologist and professor of medicine at Mayo Clinic in Rochester, Minnesota, said at the American College of Gastroenterology Annual Meeting. Control of IBD has been felt to be fundamental for
Miguel Regueiro, MD, chair of the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, discusses how to position therapies for the treatment of inflammatory bowel disease.
An estimated 30-50%, and possible 60%, of patients with inflammatory bowel disease (IBD) turn to complementary and alternative medicines (CAM’s) to ease symptoms and exert more control over their treatment. Very few studies have evaluated CAM’s, and many of the studies were small, poorly designed, and uncontrolled. Predictors of CAM use include dissatisfaction with conventional therapies,
Dr. Jonathan Kay of the University of Massachusetts Medical School told the 2018 Interdisciplinary Autoimmune Summit that biosimilar competition in Europe has reduced drug costs, made biosimilars more available and increased market share for some bio-originators. The European Union has approved 41 biosimilar drugs while the FDA has approved nine. Biosimilars in Europe lead to
Research published in the journal Alimentary Pharmacology & Therapeutics found ulcerative colitis patients with higher BMIs had a greater likelihood of biologic treatment failure. Increases in BMI also were associated with a higher risk of surgery or hospitalization. The reasons might be related to endogenous steroid production, misuse of medical steroids, or underdosing of conventional
Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). A recent study finds that pretreatment α4β7 expression and α4β7 receptor saturation during maintenance therapy were identified as candidate biomarkers for vedolizumab response. This assay leads to promise that we will be able to identify good candidates for biologic therapies
